Apple’s New Era: What the Tim Cook to John Ternus Transition Means for the World’s Most...
Apple (NASDAQ: AAPL) has confirmed that Tim Cook will step down as chief executive officer…
- ASX: PTX
Prescient Therapeutics Ltd
Share Price and News
ASX BIG FOUR - LIVE SNAPSHOT
SELL
Whitehaven Coal
(ASX:WHC)
Paul Flynn
01/03/2026
$8.7m
BUY
Elixir Energy
(ASX:EXR)
Featured
SELL
Aspen Group
(ASX:APZ)
David Dixon
03/03/2026
$11.4m
BUY
Lovisa
(ASX:LOV)
Brett Blundy
04/03/2026
$6.8m
— Copmany Overview
Introduction to Prescient Therapeutics
Prescient Therapeutics (ASX:PTX) is an ASX-listed oncology drug developer. Its lead compound is a small molecule called PTX-100, a potential future treatment for T-Cell Lymphoma. It has two cell therapy platform technologies as well: OmniCAR, which allows CAR-T therapy products to be developed, and CellPryme, which allows enhanced adoptive cell therapy performance. Of these assets, PTX-100 has the most potential to create shareholder value in the short-term, given encouraging Phase 1 data as well as the lack of current treatment options for T-Cell Lymphoma and dire outlook for patients. PTX is currently in Phase 2 and could gain accelerated FDA approval if and when this trial is successful.
Prescient Therapeutics' History
Prescient Therapeutics was founded in 2014 when bio-entrepreneur Paul Hopper licensed the rights to PTX-100 from Yale University. He then listed the company on the ASX in a reverse shell transaction, taking over Virax. A Phase 1 study was undertaken in 2019 but was initially just a dose escalation study. Phase 1b was completed in 2021 with an excellent safety profile and clinical signal. In 2022, an expansion cohort was recruited to focus specifically on T-Cell Lymphoma, and the company obtained Orphan Drug Designation status for the first time. OmniCAR was picked up in May 2020, being licensed from the University of Pennsylvania and Oxford University. PTX was also working on CellPryme, but only took it out of ‘stealth mode’ in 2022. 2023 saw solid clinical trial results from Phase 1, headlined by a Clinical Benefit Rate of 66% – patients who either saw complete eradication of the disease or some clinical response. This led to the company beginning Phase 2 in May 2025.
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
— Forward View
Future Outlook Prescient Therapeutics (ASX: PTX)
The next catalyst for the company will be the Phase 2 trial, which is underway. It will enrol a total of 75 patients, across 15 sites globally focusing on Relapsed and Refractory Cutaneous T-cell lymphomas. PTX hopes that this trial will be a success and that if so, PTX-100 could be submitted for FDA approval if and when it passed this study without the need for a Phase 3 study. Assuming success in all regards (FDA approval to the Phase 2 trial to be pivotal, successful Phase 2 results and FDA approval for commercialisation), commercialisation could occur in as little as 2-3 years from now. PTX aims to initially seek approval for CTCL and then leverage this for a separate PTCL (Peripheral T-cell lymphoma) registration study.
— Our Assessment
Is Prescient Therapeutics a Good Stock to Buy?
Investing in Prescient Therapeutics is risky as is the case with any clinical stage biotech. Nonetheless, it has several advantages over its peers including having an Orphan Drug, having commenced a potentially pivotal clinical trial in less than 12 months and targeting a disease for which there are no treatments for.
— Our Stock Analysis
Related Articles
How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!
Knowing how to read a balance sheet is a key skill investors need to know,…
Adisyn (ASX:AI1) Graphene Breakthrough, What Investors Need To Know
Adisyn may have a fix for the Chip Industry's Wiring Problem
Think about the wiring…
NEXTDC (ASX:NXT) Record 667MW Contracted & A$2.2B Capital Plan
S4 hits 71% contracted as utilisation jumps 60% to 667MW
NextDC (ASX:NXT) has added 250MW…
TSMC’s (NSDQ:TSM) Money Printer, March Revenue $13.1B, Margins Hit 58%
Record Margins, AI Demand Still Accelerating
TSMC (NSDQ:TSM) continues to show real pricing power. Demand…
ASML (NASDAQ:ASML) Q1 sales +15%, but system shipments slowed and stock fell 7%
Net orders beat revenue 1.2x, yet investors punished machine sales
ASML (NASDAQ:ASML) sits at the…
— Faq
Frequently Asked Questions
What distinguishes Prescient Therapeutics' PTX-100 in the fight against cancer?
PTX-100 is unique as it’s the only clinical-stage inhibitor of the RhoA pathway, targeting a crucial aspect of cancer cell growth. Its ability to disrupt multiple cancer circuits, including Ras, Ral, and Rac, provides a novel approach to attacking aggressive cancer types.
How does Prescient's CAR-T cell therapy platform differ from traditional therapies?
Prescient’s OmniCAR platform offers a dynamic approach to CAR-T therapy. Unlike conventional static CAR-T treatments, OmniCAR allows post-infusion control of cell activity and targets multiple cancer markers simultaneously or sequentially, offering a more adaptable and potentially effective cancer treatment.
What recent advancements has Prescient Therapeutics made in clinical trials?
Prescient completed a Phase 1b study for PTX-100 and is currently in Phase 2. The study will focus on Relapsed and Refractory Cutaneous T-cell lymphomas.
What is the significance of Prescient Therapeutics presenting at the ASH conference?
Presenting at the American Society of Hematology (ASH) conference marks a significant validation for Prescient. This prestigious global event acknowledges their groundbreaking work in hematology, showcasing their research to an international audience of experts and potentially accelerating collaboration and development.
What are the main risks of investing in Prescient Therapeutics?
As with any clinical-stage biotech, the primary risk is clinical trial failure for PTX-100 or the CAR-T therapy platform, which could materially impair share price. Prescient is pre-revenue and dependent on periodic capital raisings to fund its trials. Additional considerations include regulatory approval timelines, competition in the oncology space, and the time required to advance programs toward partnering or commercialisation.
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
